that’s the issue with using patient derived autologous t-cells, they’re generally already damaged/diminished from previous lines of treatment. These cells are already compromised, before having to have a CAR added to them and then expanded into the millions
IMO donor derived allogeneic cells, from already healthy people, is the future of cell therapy, which I’m pretty sure NK Cells are.
- Forums
- ASX - By Stock
- CHM
- Chimeric the science explained part 5
CHM
chimeric therapeutics limited
Add to My Watchlist
16.7%
!
0.4¢

Chimeric the science explained part 5, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $11.37M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $9.689K | 2.768M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
75 | 71790139 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 86946524 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
75 | 71790139 | 0.003 |
29 | 24940488 | 0.002 |
14 | 64914000 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 86946524 | 26 |
0.005 | 39943562 | 25 |
0.006 | 17929018 | 21 |
0.007 | 6512518 | 7 |
0.008 | 7317101 | 5 |
Last trade - 12.54pm 01/08/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
AFP
AFT PHARMACEUTICALS LIMITED
Hartley Atkinson, CEO & Founder
Hartley Atkinson
CEO & Founder
Previous Video
Next Video
SPONSORED BY The Market Online